Home
Off-the-shelf
Humanized mice (target-specific)
Pan hCD3
Humanized mice (target-specific)

Preclinical Pan hCD3 mouse model

Pan hCD3 immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

‍

Contact Us

Applications of the Pan hCD3 mouse

  • Efficacy assessment of T-cell engagers (notably, in tumor inhibition assessment and treatment of autoimmune diseases)
  • Safety assessment (inducing cytokine release syndrome (CRS) via treatment with anti-CD3 antibodies)

‍

Features of the Pan hCD3 mouse

  • The stability of the CD3 complex is maintained
  • Fully functional mouse immune system

Validation

Related resources and publications

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

TME

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

pulmonary hypertension (PH)

primary sclerosing cholangitis (PSC)

postpartum depression (PPD)

pemphigus vulgaris

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Case studies
(
0
)
CommentarIes
(
0
)
Scientific Articles
(
0
)
PosterS
(
0
)
No results
Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

6 min read
-
Jun 2022
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

3 min read
-
Mar 2022
Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

5 min read
-
Mar 2022
A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

8 min read
-
Feb 2021
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Sci Rep

Feb 2022
Highlighted article
read the comment
(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

CD3 binding T-cell engagement

Nov 2023
CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Nov 2022
Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

Apr 2022
No results

Discover related products to

Pan hCD3

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
T-cell engager
CD3
Mouse

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

CD3
Mouse
CD28
T-cell engager

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

Preclinical Pan hCD3 mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.